SequelSEC

ZyVersa Therapeutics, Inc. ZVSA

Pharmaceutical Preparations · CIK 0001859007 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-03-31
Operating income
-$1.30M
Fiscal year ended 2026-03-31
Free cash flow
Unavailable
Fiscal year ended 2026-03-31

ZyVersa Therapeutics, Inc. (ZVSA) reported net income of -$1.79M for the fiscal year ended 2026-03-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ZyVersa Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ZyVersa Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$1.30M-$551.86K-$20.75MUnavailableUnavailable-$1.29M-$2.27MUnavailableUnavailable-$13.93M
Net income-$1.79M-$678.57K-$19.81MUnavailableUnavailable-$1.42M-$2.40MUnavailableUnavailable-$13.34M
Research & development$57.62K$79.24K$365.05KUnavailableUnavailable$121.24K$436.04KUnavailableUnavailable$257.11K
Weighted-average diluted sharesshares 8.10MUnavailableshares 7.74MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailable-$678.57K-$20.66MUnavailableUnavailable-$1.42M-$2.40MUnavailableUnavailable-$13.93M
Income tax expenseUnavailable$0-$851.66KUnavailableUnavailable-$2.96K$0UnavailableUnavailable-$596.07K
Diluted EPS$-0.22Unavailable$-2.56UnavailableUnavailableUnavailable$-2.43UnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$1.25M$472.62K$1.74MUnavailableUnavailable$1.17M$1.83MUnavailableUnavailable$1.52M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

ZyVersa Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Cash & equivalentsUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Total assets$742.22K$463.45K$1.04MUnavailableUnavailable$20.60M$19.42MUnavailableUnavailable$22.11M
Current assets$742.22K$463.45K$995.53KUnavailableUnavailable$1.72M$390.42KUnavailableUnavailable$3.35M
Total liabilities$14.87M$12.85M$12.77MUnavailableUnavailable$12.08M$12.40MUnavailableUnavailable$11.04M
Current liabilities$14.87M$12.85M$12.77MUnavailableUnavailable$11.23M$11.54MUnavailableUnavailable$10.19M
Total equity incl. NCI-$14.12M-$12.39M-$11.73MUnavailableUnavailable$8.52M$7.03MUnavailableUnavailable$11.07M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$10.24M$10.12M$9.81MUnavailableUnavailable$9.34M$9.28MUnavailableUnavailable$8.43M

Cash flow

ZyVersa Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Operating cash flow-$799.12K-$413.69K-$1.41MUnavailableUnavailable-$1.21M-$614.14KUnavailableUnavailable-$2.79M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flow$1.00M-$12.51K$1.86MUnavailableUnavailable$2.62M$617.58KUnavailableUnavailable$4.35M
Net change in cash$200.88K-$426.20K$455.89KUnavailableUnavailable$1.41M$3.44KUnavailableUnavailable$1.56M
Stock-based compensation$55.87K$17.35K$73.99KUnavailableUnavailable$160.66K$160.66KUnavailableUnavailable$296.72K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

ZyVersa Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.05x0.04x0.08xUnavailableUnavailable0.15x0.03xUnavailableUnavailable0.33x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ZVSA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-19View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-12View SEC filing
10-K · Filed 2025-03-27View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

14 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationinconsistent2025-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.